https://doi.org/10.1038/s41366-025-01749-x

TLDR: GLP-1 and SGLT-2 drugs have been associated with EKA in the literature; Treating physicians need to be aware of ketone levels of their patients, or at least keep the EKA as a possible differential diagnosis. This hints at a underlying mechanism of benefit between ketogenic metabolism and these drugs.

https://doi.org/10.1016/j.clinthera.2016.11.002

SGLT2 inhibitors have been associated with increases in ketone-associated adverse events.

these data suggest a causal relationship between SGLT2 inhibitors and an asymptomatic rise in ketone bodies